![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1c1d46c3-5cce-4707-a74a-3c3b160780ac/gr2_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram](https://www.researchgate.net/publication/343940004/figure/fig1/AS:983955708854272@1611604730580/a-Progression-free-survival-PFS-and-b-overall-survival-OS-CI-confidence.png)
a) Progression-free survival (PFS) and (b) overall survival (OS). CI,... | Download Scientific Diagram
![NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter](https://pbs.twimg.com/media/DJbom06UEAAQejo.jpg)
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial - Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b316d514-43f8-43ee-b998-0cbc54128a98/gr1_lrg.jpg)
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
![Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/skin/melanoma_slide_thumb/melanoma_slide_thumb-2.png?rev=9a4124158ba64e8ab42f202682b054e6)
Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
![Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0112-1/MediaObjects/41669_2018_112_Fig2_HTML.png)
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | SpringerLink
![Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs41669-018-0080-5/MediaObjects/41669_2018_80_Fig3_HTML.gif)
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
![Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider](https://provider.skincancer.org/wp-content/uploads/Figure-1-chart.jpg)
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/52c41546-392d-4834-a98c-2fe8fac43e2c/gr2_lrg.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
![Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e3947409-2537-4e51-bb60-7d3f7818fc2d/gr4.jpg)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
![Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials - The Lancet Oncology Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2117427417/2085530586/gr1.jpg)
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials - The Lancet Oncology
![PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/05d8ec52e94baed4fc4663945cff5b66471673c8/4-Figure3-1.png)
PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar
![SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape](https://minio.scielo.br/documentstore/1806-9282/4LH988cHYNSgxBPmP7znMwG/5120c2a43d233dc44210c5d2af68f7afd8880a38.jpg)
SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape
![Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation](https://www.aimatmelanoma.org/wp-content/uploads/Blogging-Tips-LinkedIn-Post-Header-25.png)
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation
![The Lancet Oncology on Twitter: "Presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial The Lancet Oncology on Twitter: "Presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial](https://pbs.twimg.com/media/DqIWGzAXcAAfX2s.jpg)
The Lancet Oncology on Twitter: "Presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
![CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200765/full/dn21_itj_advancedmelanoma_fig_thumbnail.png)
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
![First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/843ac863-9a1b-474b-a52e-4569cc79b63d/gr1_lrg.jpg)